Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RECONNECT-S ALPHA: A Non-interventional Study to Observe Real-life Allocation of Antipsychotics in the Acute Inpatient Management of Schizophrenia

NCT01394601 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01394601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01394601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RECONNECT-S ALPHA: A Non-interventional Study to Observe Real-life Allocation of Antipsychotics in the Acute Inpatient Management of Schizophrenia
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
August 31, 2011
Completion date
December 31, 2011
Enrollment
600 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia